The preliminary work in establishing the PATHWAYS clinical trial into the prescription of puberty blockers for children and young people with gender incongruence has been paused, following new concerns raised by the medicines regulator, the MHRA. Discussions between the MHRA and the trial sponsor, King’s College London, will begin next week to address the new […]